• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

创新临床组织模式以确保医用大麻管理的适宜性和质量:一个意大利地区的案例

Innovative Clinical-Organizational Model to Ensure Appropriateness and Quality in the Management of Medical Cannabis: An Italian Regional Case.

作者信息

Russo Eleonora, Cannas Clara, Rivetti Maria Susanna, Villa Carla, Rebesco Barbara

机构信息

Section of Medicinal and Cosmetic Chemistry, Department of Pharmacy, University of Genova, 16132 Genova, Italy.

Drug Policy Department, A.Li.Sa, 16121 Genova, Italy.

出版信息

Healthcare (Basel). 2021 Oct 22;9(11):1425. doi: 10.3390/healthcare9111425.

DOI:10.3390/healthcare9111425
PMID:34828472
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8625658/
Abstract

This work focuses on the clinical-organizational model implemented in an Italian region (Liguria) to streamline the access procedures to galenic cannabis preparations. The competent local health care authority that takes care of tracing a virtuous path to obtain common, uniform and shared protocols and ensure high standards of care is A.Li.Sa. (Azienda Ligure Sanitaria), a public organization with the function of coordination, direction and governance of the health care in the regional hospitals and health facilities. To this purpose, different working groups and a board meeting have been set up with the main role to define and develop technical standards to be applied to the prescription, preparation and dispensing of pharmaceutical forms based on therapeutic cannabis. In particular, the galenic preparations provided by the Italian Ministry of Health, described in detail in the regional standard operating protocols, are described and discussed. Moreover, the most significant data monitored from 2018 to 2020 and collected by hospitals and the evaluation of those derived from local pharmacies and health facilities are presented, discussed and compared in regards to their adherence and coherence with the Italian Institute of Health (ISS) data.

摘要

这项工作聚焦于意大利利古里亚大区实施的临床组织模式,以简化药用大麻制剂的获取程序。负责探寻一条良性路径以获得通用、统一且共享的协议并确保高标准医疗服务的当地主管卫生当局是利古里亚卫生局(Azienda Ligure Sanitaria),这是一个具有协调、指导和管理该地区医院及卫生机构医疗保健功能的公共组织。为此,已成立了不同的工作组和董事会会议,其主要职责是定义和制定适用于基于治疗性大麻的药物剂型的处方、制备和配药的技术标准。特别是,对意大利卫生部提供的药用制剂进行了描述和讨论,这些制剂在地区标准操作协议中有详细说明。此外,还展示、讨论并比较了2018年至2020年期间医院监测到的最重要数据以及从当地药房和卫生机构收集的数据,并分析了它们与意大利卫生研究院(ISS)数据的一致性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ba9/8625658/d5dd2593d2ad/healthcare-09-01425-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ba9/8625658/d476eac9baf8/healthcare-09-01425-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ba9/8625658/d5dd2593d2ad/healthcare-09-01425-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ba9/8625658/d476eac9baf8/healthcare-09-01425-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ba9/8625658/d5dd2593d2ad/healthcare-09-01425-g002.jpg

相似文献

1
Innovative Clinical-Organizational Model to Ensure Appropriateness and Quality in the Management of Medical Cannabis: An Italian Regional Case.创新临床组织模式以确保医用大麻管理的适宜性和质量:一个意大利地区的案例
Healthcare (Basel). 2021 Oct 22;9(11):1425. doi: 10.3390/healthcare9111425.
2
Critical Care Network in the State of Qatar.卡塔尔国重症监护网络。
Qatar Med J. 2019 Nov 7;2019(2):2. doi: 10.5339/qmj.2019.qccc.2. eCollection 2019.
3
-Based Oral Emulsion for Medical Purposes to Meet the Needs of Patients: Formulation, Quality and Stability.基于满足患者需求的药用口服乳剂:配方、质量与稳定性。
Pharmaceutics. 2022 Feb 25;14(3):513. doi: 10.3390/pharmaceutics14030513.
4
Phytocannabinoids Profile in Medicinal Cannabis Oils: The Impact of Plant Varieties and Preparation Methods.药用大麻油中的植物大麻素概况:植物品种和制备方法的影响
Front Pharmacol. 2020 Nov 13;11:570616. doi: 10.3389/fphar.2020.570616. eCollection 2020.
5
Development of Standard Operating Protocols for the Optimization of -Based Formulations for Medical Purposes.用于优化医疗用途的基于-的制剂的标准操作规范的制定。 你提供的原文中“-Based”部分似乎缺失了具体内容,请你检查一下是否完整准确。
Front Pharmacol. 2019 Jun 25;10:701. doi: 10.3389/fphar.2019.00701. eCollection 2019.
6
The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.医院环境中患者与护士以患者为中心的沟通体验:一项定性系统评价方案
JBI Database System Rev Implement Rep. 2015 Jan;13(1):76-87. doi: 10.11124/jbisrir-2015-1072.
7
Education and training among Italian postgraduate medical schools in public health: a comparative analysis.意大利公共卫生领域研究生医学院校的教育与培训:一项比较分析。
Ann Ig. 2014 Sep-Oct;26(5):426-34. doi: 10.7416/ai.2014.2002.
8
[Guidelines for health surveillance of health care workers exposed to biological risks set up by the Italian Society for Occupational Health and Industrial Hygiene: application in health facilities of the Regional Health Administration--District No. 7, Ancona].[意大利职业健康与工业卫生协会制定的医护人员生物风险暴露健康监测指南:在安科纳第7区地方卫生局下属医疗机构中的应用]
Med Lav. 2005 Jan-Feb;96(1):52-62.
9
Innovative methods for the preparation of medical Cannabis oils with a high content of both cannabinoids and terpenes.创新方法制备高含量大麻素和萜烯的医用大麻油。
J Pharm Biomed Anal. 2020 Jul 15;186:113296. doi: 10.1016/j.jpba.2020.113296. Epub 2020 Apr 6.
10
[Audit as a tool to assess and promote the quality of medical records and hospital appropriateness: metodology and preliminary results].[审计作为评估和提升病历质量及医院适宜性的工具:方法与初步结果]
Ig Sanita Pubbl. 2015 Mar-Apr;71(2):139-56.

引用本文的文献

1
Cannabinoid-Based Ocular Therapies and Formulations.基于大麻素的眼部治疗方法与制剂
Pharmaceutics. 2023 Mar 27;15(4):1077. doi: 10.3390/pharmaceutics15041077.

本文引用的文献

1
Analysis of Cannabinoids Concentration in Cannabis Oil Galenic Preparations: Harmonization between Three Laboratories in Northern Italy.大麻油盖伦制剂中大麻素浓度分析:意大利北部三个实验室之间的协调
Pharmaceuticals (Basel). 2021 May 14;14(5):462. doi: 10.3390/ph14050462.
2
The neuropharmacology of cannabinoid receptor ligands in central signaling pathways.大麻素受体配体在中枢信号通路中的神经药理学。
Eur J Neurosci. 2022 Feb;55(4):909-921. doi: 10.1111/ejn.14982. Epub 2020 Dec 5.
3
Development of Standard Operating Protocols for the Optimization of -Based Formulations for Medical Purposes.
用于优化医疗用途的基于-的制剂的标准操作规范的制定。 你提供的原文中“-Based”部分似乎缺失了具体内容,请你检查一下是否完整准确。
Front Pharmacol. 2019 Jun 25;10:701. doi: 10.3389/fphar.2019.00701. eCollection 2019.
4
Extraction Method and Analysis of Cannabinoids in Cannabis Olive Oil Preparations.大麻油制剂中大麻素的提取方法和分析。
Planta Med. 2018 Mar;84(4):242-249. doi: 10.1055/s-0043-123074. Epub 2017 Dec 4.
5
Cannabidiol (CBD) and its analogs: a review of their effects on inflammation.大麻二酚(CBD)及其类似物:对其抗炎作用的综述
Bioorg Med Chem. 2015 Apr 1;23(7):1377-85. doi: 10.1016/j.bmc.2015.01.059. Epub 2015 Feb 7.
6
Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies.大麻对人类记忆功能的急性和非急性影响:神经影像学研究的批判性综述。
Curr Pharm Des. 2014;20(13):2114-25. doi: 10.2174/13816128113199990436.
7
Effects of endocannabinoid system modulation on cognitive and emotional behavior.内源性大麻素系统调节对认知和情绪行为的影响。
Front Behav Neurosci. 2011 Sep 13;5:57. doi: 10.3389/fnbeh.2011.00057. eCollection 2011.
8
Involvement of the endocannabinoid system in reward processing in the human brain.内源性大麻素系统在人类大脑奖赏加工中的作用。
Psychopharmacology (Berl). 2012 Feb;219(4):981-90. doi: 10.1007/s00213-011-2428-8. Epub 2011 Aug 6.
9
Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.新型 PET 示踪剂 [11C]OMAR 定量检测健康受试者和精神分裂症患者脑型大麻素受体 1 亚型 (CB1)
Neuroimage. 2010 Oct 1;52(4):1505-13. doi: 10.1016/j.neuroimage.2010.04.034. Epub 2010 Apr 18.
10
Chronic stress differentially regulates cannabinoid CB1 receptor binding in distinct hippocampal subfields.慢性应激以不同方式调节不同海马亚区中的大麻素CB1受体结合。
Eur J Pharmacol. 2009 Jul 1;614(1-3):66-9. doi: 10.1016/j.ejphar.2009.04.048. Epub 2009 May 6.